Biotech

All Articles

Lykos will certainly ask FDA to reconsider its own selection following denial of MDMA therapy for trauma

.Complying with a bad showing for Lykos Therapies' MDMA prospect for trauma at a current FDA advisor...

AN 2 halves roll call, stops stage 3 trial after data dissatisfy

.AN2 Therapeutics is re-thinking its own business in response to poor midphase information, swearing...

Merck pays $700M for bispecific, snooping autoimmune position and chance to challenge Amgen in cancer

.Merck &amp Co. is actually spending $700 million in advance to test Amgen in a blood stream cancer ...

Gilead pays for J&ampJ $320M to leave licensing bargain for seladelpar

.Along With Gilead Sciences almost an FDA decision for its own liver health condition medicine selad...

' All palms on deck' at Lilly as peers target being overweight market

.Chief executive officer David Ricks can easily find the providers putting together outdoors tents a...

Entero giving up team, moving out of workplace and pausing R&ampD

.Bed mattress Liquidators has turned Entero Therapeutics white colored as a piece. The lender bought...

Exelixis goes down ADC after deciding it is actually no suit for Tivdak

.Exelixis is quiting on its own cells element (TF)- targeting antibody-drug conjugate after concludi...

Relay loses interest in SHP2 inhibitor after Genentech leaves behind

.3 full weeks after Roche's Genentech system bowed out an SHP2 inhibitor treaty, Relay Therapy has c...

Stoke's Dravet disorder med released of predisposed professional hold

.Stoke Therapies' Dravet disorder drug has been actually without a predisposed hold, removing the me...

Fierce Biotech's Gabrielle Masson offers Strong 15 at NYSE

.Strong Biotech Partner Editor Gabrielle Masson presented the 2024 lesson of Intense 15 victors on t...